Cited by 391Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Longer Forms of Amyloid β Protein: Implications for the Mechanism of Intramembrane Cleavage by γ-Secretase

Open access
Qi-Takahara, Yue, Morishima-Kawashima, Maho, Tanimura, Yu, Dolios, Georgia, Hirotani, Naoko, Horikoshi, Yuko, Kametani, Fuyuki, Maeda, Masahiro +3 more·2005·The Journal of Neuroscience

Abstract

γ-Cleavage of β-amyloid precursor protein (APP) in the middle of the cell membrane generates amyloid β protein (Aβ), and ϵ-cleavage, ∼10 residues downstream of the γ-cleavage site, releases the APP intracellular domain (AICD). A significant link between generation of Aβ and AICD and failure to detect AICD41-99 led us to hypothesize that ϵ-cleavage generates longer Aβs, which are then processed to Aβ40/42. Using newly developed gel systems and an N-end-specific monoclonal antibody, we have identified the longer Aβs (Aβ1-43, Aβ1-45, Aβ1-46, and Aβ1-48) within the cells and in brain tissues. The production of these longer Aβs as well as Aβ40/42 is presenilin dependent and is suppressed by {1 S-benzyl-4 R-[1 S-carbamoyl-2-phenylethylcarbamoyl-1 S-3-methylbutylcarbamoyl]-2 R-hydroxy-5-phenylpentyl}carbamic acid tert-butyl ester, a transition state analog inhibitor for aspartyl protease. In contrast,N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester, a potent dipeptide γ-secretase inhibitor, builds up Aβ1-43 and Aβ1-46 intracellularly, which was also confirmed by mass spectrometry. Notably, suppression of Aβ40 appeared to lead to an increase in Aβ43, which in turn brings an increase in Aβ46, in a dose-dependent manner. We therefore propose an α-helical model in which longer Aβ species generated by ϵ-cleavage is cleaved at every three residues in its carboxyl portion.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.1575-04.2005

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Qi-Takahara, Y., Morishima-Kawashima, M., Tanimura, Y., Dolios, G., Hirotani, N., Horikoshi, Y., Kametani, F., Maeda, M., Saido, T. C., Wang, R., & Ihara, Y.
Affiliations
  • The University of Tokyo (JP)
  • Icahn School of Medicine at Mount Sinai (US)
  • Tokyo Institute of Psychiatry (JP)
  • RIKEN (JP)
Corresponding author
Ihara, Yasuo
Venue
The Journal of Neuroscience
Published
2005-01-12
Volume
25
Issue
2
Pages
436-445
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2097750046
Cited by
391
References
5
Citations by year
2026: 4 · 2025: 7 · 2024: 17 · 2023: 20 · 2022: 14 · 2021: 14 · 2020: 17 · 2019: 22 · 2018: 14 · 2017: 15 · 2016: 24 · 2015: 16 · 2014: 20 · 2013: 31 · 2012: 29
FWCI
13.42
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology
  • National Institutes of Health
  • Japan Society for the Promotion of Science
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, gamma-secretase, APP intracellular domain, presenilin, aspartyl protease inhibitors, Aβ40, intramembrane cleavage, Alzheimer's disease
MeSH terms
Alzheimer Disease, Animals, Brain, Cell Line, Cricetulus, Dipeptides, Cricetinae, Humans, Male, Membrane Proteins, Mice, Transgenic, Endopeptidases, Subcellular Fractions, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Protein Structure, Secondary, Protein Structure, Tertiary, Amino Acid Motifs, Mice, Presenilin-1, Presenilin-2, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review